Radytta

Radytta is a preclinical-stage biotechnology company focused on the discovery and development of novel therapies for autoimmune and inflammatory diseases. The company leverages deep expertise in immunology to target specific pathways within the innate immune system, particularly those involved in chronic inflammation. Founded by industry veterans with extensive experience at Genentech, Radytta aims to address significant unmet needs in the immunology and inflammation (I&I) space. The company is currently advancing its internal pipeline of small molecule therapeutics toward clinical development. Radytta is backed by prominent life science investors, including Westlake Village BioPartners.